Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Liquefaction of Autographa californica nucleopolyhedrovirus-infected insects is dependent on the integrity of virus-encoded chitinase and cathepsin genes.
The role of the Autographa californica nucleopolyhedrovirus (AcMNPV)-encoded chitinase in virus pathogenesis in Trichoplusia ni larvae is examined, demonstrating that despite 57% sequence identity, the two proteins have distinct enzymic activities.
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Oral or i.p. administration of SU6668 in athymic mice resulted in significant growth inhibition of a diverse panel of human tumor xenografts of glioma, melanoma, lung, colon, ovarian, and epidermoid origin, and intravital multifluorescence videomicroscopy of C6glioma xenografteds in the dorsal skinfold chamber model revealed thatSU6668 treatment suppressed tumor angiogenesis.
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Data supported the clinical development of SNS-032 in diseases that require short-lived oncoproteins for survival, as it was hypothesized that transient inhibition of transcription by S NS-032 would decrease antiapoptotic proteins, resulting in cell death.
Red-Shifted Excitation Mutants of the Green Fluorescent Protein
- S. Delagrave, R. Hawtin, Chris M. Silva, Mary M. Yang, D. Youvan
- Biology, ChemistryBio/Technology
- 1 February 1995
Using optimized combinatorial mutagenisis techniques and digital imaging Spectroscopy (DIS), we have insulated mutants of the cloned Aequorea victoria green fluorescent protein (GFP)that show…
Identification and preliminary characterization of a chitinase gene in the Autographa californica nuclear polyhedrosis virus genome.
Phylogenetic analyses indicate that AcMNPV, or an ancestral baculovirus, acquired the chitinase gene from a bacterium via horizontal gene transfer.
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
- A. Conroy, David E. Stockett, R. Hawtin
- Biology, MedicineCancer Chemotherapy and Pharmacology
- 24 January 2009
These results demonstrate SNS-032 target modulation of CDKs 2, 7 and 9, and establish 6 h exposure as sufficient to commit RPMI-8226 MM cells to apoptosis, and support the ongoing clinical study of S NS-032 in MM and CLL.
Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II
As a first-in-class anticancer quinolone derivative, voreloxin is a toposiomerase II-targeting agent with a unique mechanistic signature and may advance the understanding of structure-activity relationships to develop safer and more effective topoisomerase I-targeted therapies for the treatment of cancer.
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
A phase 3 trial of vosaroxin plus cytarabine was initiated in patients with relapsed/refractory acute myeloid leukemia, with complete remission rate of 25% and complete remission/complete remission with incomplete blood count recovery rate was 28%.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
- G. Masucci, A. Cesano, M. Thurin
- Biology, MedicineJournal of Immunotherapy for Cancer
- 15 November 2016
Pre-analytical and analytical as well as clinical and regulatory aspects of the validation process as applied to predictive biomarkers for cancer immunotherapy and examples of biomarker assays that have shown preliminary evidence of an association with clinical benefit from immunotherapeutic interventions are discussed.
AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
The identification of AKT signaling as being associated with GO resistance in vitro may provide a novel approach to improve the in vivo efficacy of GO/calicheamicin-γ1 and, by extrapolation, other DNA damage-based therapeutics.